title: Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.
abstract: The discovery of the biological functions of the interleukin-23/-17 axis led to the identification of IL-23 and IL-17 as important participants in the pathogenesis of several immune-mediated diseases. Therapeutic agents targeting these cytokines and/or their receptors have now been developed as potential treatment strategies for common immune-mediated diseases. Anti-IL-17 and anti-IL-12/-23 regimens appear particularly effective in psoriasis, with promising results in spondyloarthropathies also emerging. Overall, these agents appear well tolerated, with adverse-event rates that are commensurate with those in other biologic treatment programs. The strategic utility of these new agents, however, remains uncertain, and further studies will be required to determine their place in the context of existing conventional and biologic immune-modifying agents.
authors.affiliation: Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8QQ, United Kingdom; email: Iain.McInnes@glasgow.ac.uk , Stefan.Siebert@glasgow.ac.uk.
authors.forename: George E
authors.initials: GE
authors.lastname: Fragoulis
authors.affiliation: Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8QQ, United Kingdom; email: Iain.McInnes@glasgow.ac.uk , Stefan.Siebert@glasgow.ac.uk.
authors.forename: Stefan
authors.initials: S
authors.lastname: Siebert
authors.affiliation: Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8QQ, United Kingdom; email: Iain.McInnes@glasgow.ac.uk , Stefan.Siebert@glasgow.ac.uk.
authors.forename: Iain B
authors.initials: IB
authors.lastname: McInnes
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D053759:Interleukin-23 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D020381:Interleukin-17; D053759:Interleukin-23; C000588857:guselkumab; C571216:brodalumab; C544528:briakinumab; C549079:ixekizumab; C000598434:tildrakizumab; C555450:secukinumab; D000069549:Ustekinumab
keywords: IL-23/IL-17 axis; interleukin-17; interleukin-23; psoriasis; psoriatic arthritis